We are live on ! Find out more
ICUI icon

ICU Medical

260 hedge funds and large institutions have $3.04B invested in ICU Medical in 2019 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 105 increasing their positions, 73 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more call options, than puts

Call options by funds: $22.5M | Put options by funds: $5.11M

44% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 73

1.91% less ownership

Funds ownership: 94.74%92.83% (-1.9%)

4% less funds holding

Funds holding: 270260 (-10)

20% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 51

38% less capital invested

Capital invested by funds: $4.88B → $3.04B (-$1.84B)

80% less funds holding in top 10

Funds holding in top 10: 51 (-4)

Holders
260
Holders Change
-10
Holders Change %
-3.7%
% of All Funds
5.7%
Holding in Top 10
1
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-80%
% of All Funds
0.02%
New
41
Increased
105
Reduced
73
Closed
51
Calls
$22.5M
Puts
$5.11M
Net Calls
+$17.4M
Net Calls Change
-$831K
Name Holding Trade Value Shares
Change
Change in
Stake
Charles Schwab
26
Charles Schwab
California
$21M +$4.86M +24,423 +23%
EVM
27
Eaton Vance Management
Massachusetts
$20.8M +$225K +1,128 +0.9%
Invesco
28
Invesco
Georgia
$19.5M -$60.9M -305,837 -71%
RJA
29
Raymond James & Associates
Florida
$19M +$298K +1,496 +1%
EAM
30
Eagle Asset Management
Florida
$18.3M +$2.14M +10,747 +10%
AQR Capital Management
31
AQR Capital Management
Connecticut
$17.1M -$21.1M -105,791 -49%
SCP
32
Sandhill Capital Partners
New York
$17.1M +$1.19M +6,000 +6%
PVI
33
Pura Vida Investments
New York
$14.8M +$2.66M +13,381 +17%
Principal Financial Group
34
Principal Financial Group
Iowa
$13.3M +$1.96M +9,840 +13%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$12.9M +$14.1M +70,894 +698%
Bank of America
36
Bank of America
North Carolina
$12.6M +$1.71M +8,598 +12%
Ameriprise
37
Ameriprise
Minnesota
$12.6M +$2.4M +12,031 +18%
Millennium Management
38
Millennium Management
New York
$12.1M -$42.9M -215,485 -74%
AAM
39
AMI Asset Management
California
$11.7M +$808K +4,060 +6%
GH
40
GAM Holding
Switzerland
$10.9M -$3.38M -17,000 -20%
RJFSA
41
Raymond James Financial Services Advisors
Florida
$10.7M -$4.6M -23,123 -26%
Goldman Sachs
42
Goldman Sachs
New York
$10.4M -$3.23M -16,208 -20%
TD Asset Management
43
TD Asset Management
Ontario, Canada
$10.1M -$115K -579 -0.9%
Fisher Asset Management
44
Fisher Asset Management
Washington
$9.74M
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$9.61M -$1.03M -5,174 -8%
GF
46
Gabelli Funds
New York
$8.71M +$159K +800 +1%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$8.51M +$751K +3,771 +8%
Public Employees Retirement Association of Colorado
48
Public Employees Retirement Association of Colorado
Colorado
$8.49M
HA
49
Homestead Advisers
Virginia
$8.38M -$2.19M -11,000 -17%
SI
50
Scout Investments
Missouri
$8.04M -$732K -3,679 -7%

ICUI Hedge Fund Activity: Q3 2019 in Review

260 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ICU Medical (ICUI) for Q3 2019, worth a combined $3.04B — down 38% from $4.88B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of ICUI and 41 opened new positions — a net loss of 10 holders — while 73 trimmed existing stakes and 105 added.

The largest buyer was Nuance Investments, adding an estimated $99.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $171M.

  • 260 institutional investors held ICU Medical (ICUI) as of Q3 2019, down from 270 in Q2 2019.
  • Funds reported $3.04B of ICU Medical stock for Q3 2019, down 38% quarter-over-quarter.
  • 41 funds opened new ICU Medical positions in Q3 2019 and 51 closed out, a net change of -10 holders.
  • The largest ICU Medical buyer in Q3 2019 was Nuance Investments, an estimated $99.7M added.
  • The largest ICU Medical seller in Q3 2019 was T. Rowe Price Associates, an estimated $171M sold.

Based on aggregated 13F filings for Q3 2019.